Differences in clinical characteristics and reported quality of life of men and women undergoing cardiac resynchronization therapy

Bruce L. Wilkoff, David Birnie, Michael R. Gold, Ahmad S. Hersi, Sandra Jacobs, Bart Gerritse, Kengo Kusano, Christophe Leclercq, Wilfried Mullens and Gerasimos Filippatos

Abstract

Aims Response to cardiac resynchronization therapy (CRT) is known to be associated with a number of clinical characteristics, including QRS duration and morphology, gender, height, and the aetiology of heart failure (HF). We assessed the relation of gender and baseline characteristics with QRS duration and Kansas City Cardiomyopathy Questionnaire.

Methods and results AdaptResponse is a global randomized trial. The trial enrolled CRT-indicated patients with New York Heart Association classes II–IV HF, left bundle branch block (QRS ≥ 140 ms in men, ≥130 ms in women), and baseline PR interval ≤200 ms. In total, 3620 patients were randomized, including 1569 women (43.3%) approaching the actual proportion of women in the HF population. Women were older and more often New York Heart Association class III or IV than men (55.6% vs. 48.7%), had less frequent ischaemic cardiomyopathy (21.2% vs. 39.5%), and had a 5.1 ms shorter QRS duration than men. Women were more often depressed (18.5% vs. 9.7%), had a significantly lower Kansas City Cardiomyopathy Questionnaire score, and had differences in medication prescriptions.

Conclusions AdaptResponse is the largest randomized CRT trial and enrolled more women than any other landmark CRT trial. Women differed from men with regard to baseline characteristics and quality of life. Whether these differences translate into clinical outcome differences will be examined further in the AdaptResponse trial.

Keywords Cardiac resynchronization therapy outcome; LV pacing; AV conduction; Left bundle branch block; Gender differences in heart failure; Kansas City Cardiomyopathy Questionnaire

Introduction

Cardiac resynchronization therapy (CRT) is an established therapy for patients with symptomatic heart failure (HF), left ventricular (LV) systolic dysfunction, and a prolonged QRS duration, which reduces HF symptoms, hospitalizations, and mortality. However, the benefit of CRT varies with limited clinical improvement or reverse remodelling observed in approximately 30–40% of device recipients. Patient sex has been reported to influence response to CRT, with an overall higher response rate, especially with regard to reverse remodelling, reported in women. Other patient characteristics, including QRS morphology and duration, dyssynchrony, scar burden, cardiomyopathy aetiology, age, height, New York Heart Association (NYHA) class, and prior HF hospitalization, have all also been associated with the extent of clinical benefit with CRT. As some of these characteristics differ between the sexes, the improved CRT response in women

© 2020 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
might be secondary to the sex-related difference in patient characteristics associated with response.

To determine whether women should be treated differently from men, a better understanding of the independent effect of sex on outcome is crucial. A lower QRS duration cut-off criterion for left bundle branch block (LBBB) has already been proposed for women. Although there are reports comparing CRT response by sex, there is a need for confirmation and further investigation in randomized controlled clinical trials well represented with women. Unfortunately, women constitute only about 20–30% of the study population of previous CRT trials so the study results have primarily reflected outcomes in men. In order to understand potential differences between men and women, we must understand the differences in clinical characteristics and their impact on clinical outcomes.

The AdaptivCRT (Medtronic plc, USA) was designed to provide ongoing automated CRT optimization and to allow for more physiologic ventricular activation and greater device longevity in patients with normal atrioventricular (AV) conduction times by reducing unnecessary right ventricular pacing. Previously published evidence suggests improved clinical outcomes, predominantly in patients with LBBB and intact AV conduction. The AdaptResponse trial seeks to test the hypothesis that the AdaptivCRT algorithm results in superior outcome compared with conventional CRT in CRT-indicated patients with normal AV conduction and LBBB. The current report describes the sex-related differences in the baseline clinical characteristics and quality of life (QoL) of the patients randomized in the AdaptResponse trial and focuses specifically on factors associated with QRS duration.

## Methods

### AdaptResponse trial design

The design of the AdaptResponse trial has been reported in detail elsewhere. Briefly, AdaptResponse is a global single-blinded randomized trial with blinded endpoint adjudication (ClinicalTrials.gov; identifier: NCT02205359), which compares AdaptivCRT to conventional CRT in patients with LBBB and PR interval ≤ 200 ms. The primary endpoint is the combined endpoint of all-cause mortality and intervention for HF decompensation.

### Inclusion and exclusion criteria

Patients could be included when they had (i) an indication for a CRT device according to the local scientific guidelines with an LV ejection fraction (LVEF) ≤ 35% and NYHA classes II, III, or IV symptoms despite optimal medical therapy; (ii) LBBB according to the Strauss criteria as determined by the physician (requires QRS duration \( \geq 140 \) ms in men, \( \geq 130 \) ms in women); (iii) normal AV conduction defined as PR interval \( \leq 200 \) ms on electrocardiogram (ECG); and (iv) sinus rhythm at time of enrolment. Previous CRT was an exclusion criterion. The AdaptResponse design manuscript provides details on the inclusion criteria and a complete overview of the exclusion criteria. Inclusion was based on investigator assessment of ECG criteria; however, screening ECGs were subsequently reviewed by a core laboratory that provided instructional feedback to investigators in case of deviation from the strict criteria.

### Protocol and data collection

Written approval from the Institutional Review Board and/or Medical Ethics Committee was obtained at all sites and each patient provided written informed consent. After informed consent, data were collected on demographics, medical history, presenting signs and symptoms, comorbidities, and concomitant treatment. The EuroQol-5D Questionnaire (EQ-5D) and Kansas City Cardiomyopathy Questionnaire (KCCQ) were used as measures of general and health-related QoL. Case report form completion and handling was performed electronically using a secure, password-protected electronic data management system for clinical studies. After baseline assessment, patients were implanted with an AdaptivCRT capable device (Medtronic plc, Minneapolis, MN, USA) and randomized 1:1 to AdaptivCRT or conventional CRT.

### Time course of the AdaptResponse trial

The first enrolment took place on 5 August 2014 and enrolment was closed on 31 January 2019. Follow-up will continue until 1100 primary endpoint events have been accrued or predefined stopping criteria are met at an interim analysis.

### Statistical analysis

Descriptive statistics were used as appropriate according to the distribution of variables. Categorical data were reported as incidence (%) and continuous data as mean ± standard deviation. Men and women were compared with Student’s t-test for continuous variables, Fisher’s exact test for nominal categorical variables, and the Cochran–Mantel–Haenszel test for trends in ordinal variables. Indexed QRS is derived by dividing QRS duration (ms) by body height (m) and indexed creatinine is derived by dividing the creatinine (mg/dL) value by body weight (kg) divided by 100.

A multivariable linear regression model was developed for QRS duration, using backward variable selection to reduce an initial model with 29 variables (known predictors of outcome in CRT patients and variables with large difference between men and women), forcing sex, age, height, NYHA class,
ischaemic aetiology, atrial fibrillation (AF), diabetes, chronic lung disease, and renal dysfunction to stay in the model. Interactions with sex were reviewed, but none were included in the final model. Body mass index is modelled as a partially linear effect with cut points at 18.5 and 30 kg/m². Women with QRS duration < 140 ms were excluded to have balanced selection criteria.

All analyses were conducted in SAS version 9.4 (SAS Institute Inc., Cary, NC, USA).

Results

A total of 3800 patients were recruited from 227 centres in 27 countries worldwide of which 3620 patients (95.3%) were randomized. The 180 subjects who were not randomized, including those who died (n = 8), did not meet the eligibility criteria (n = 103, of which 49 did not meet the normal AV conduction criterion), did not have a successful device implantation (n = 56), or revoked consent (n = 13). The core laboratory reviewed the screening ECG of 3579 of the randomized patients (98.8%) and confirmed LBBB per Strauss criteria in 3472 (95.9%) and PR ≤ 200 ms in 3482 (96.2%). The Supporting Information summarizes the geographic distribution of subjects (Supporting Information, Table S1) and lists the participating investigators per country.

Baseline characteristics

The baseline patient characteristics, laboratory findings, and QoL stratified by sex are presented in Table 1. AdaptResponse recruited a relatively high proportion of women, representing 43.3% of the randomized patients. A number of significant differences between the sexes was noted. In general, women were shorter and slightly older than men. Women were more often classified as NYHA class III or IV (55.6% vs. 48.7%), with a significantly smaller QRS duration (158.4 ± 16.7 vs. 165.9 ± 15.8 ms) and PR interval (167.7 ± 21.2 vs. 174.9 ± 20.3 ms), but larger indexed QRS (98.4 ± 10.8 vs. 94.9 ± 9.7 ms/m). A smaller proportion of women had ischaemic cardiomyopathy (21.2% vs. 39.5%) or a history of myocardial infarction (12.6% vs. 23.7%).

Comorbidities such as AF (10.3% in women vs. 14.7% in men), peripheral vascular disease (3.8% vs. 6.6%), diabetes (32.6% vs. 36.2%), sleep apnoea (8.8% vs. 12.5%), and renal dysfunction (15.5% vs. 17.9%) were more common in men compared with women. In contrast, women had a higher incidence of anaemia (8.3% vs. 5.1%), chronic lung disease (16.2% vs. 13.7%), and depression (18.5% vs. 9.7%) and reported more often underweight (2.5% vs. 1.1%) or obesity (39.8% vs. 35.3%). Higher plasma levels of creatinine in men (1.09 ± 0.76 vs. 1.27 ± 0.89 mg/dL) are explained by higher weight with indexed creatinine equal between sexes. In women, lower plasma concentrations of haemoglobin (12.7 ± 1.5 vs. 13.7 ± 1.7 g/dL) and increased incidence of hypothyroidism (14.0% vs. 5.2%) were observed.

Kansas City Cardiomyopathy Questionnaire and EuroQol-5D Questionnaire

Women had a significantly lower score on all KCCQ domains except self-efficacy (Figure 1). Large differences were seen for physical limitation (62.4 ± 25.1 vs. 72.3 ± 24.3), symptom frequency (63.1 ± 26.1 vs. 71.6 ± 24.9), symptom burden (65.2 ± 24.9 vs. 73.4 ± 23.7), and in the clinical summary score (63.3 ± 23.1 vs. 72.4 ± 22.1), all P < 0.0001. The overall summary score was 57.9 ± 23.7 in women and 65.9 ± 23.3 in men, P < 0.0001. The EQ-5D questionnaire also showed significant differences between sexes. Women reported more frequent problems in each of the five dimensions (Figure 2A), including 46.5% vs. 36.4% having problems walking, 58.5% vs. 42.2% having problems performing usual activities, and 48.7% vs. 34.2% being anxious or depressed. The self-rated overall health score (61.9 ± 20.1 vs. 64.2 ± 19.3, P < 0.001, Figure 2B) was also lower in women.

Medication

Table 2 summarizes the baseline cardiovascular medication and shows sex-related differences in treatment. Women received less angiotensin-converting enzyme inhibitors than men (47.5% vs. 54.6%) but were more often prescribed angiotensin receptor blockers (37.6% vs. 30.6%). The use of diuretics was higher in women (68.1% vs. 60.9%). No differences were seen for beta-blockers, mineralocorticoid receptor antagonists, angiotensin receptor nepriylisin inhibitors, or ivabradine. Vasodilators (10.4% vs. 12.8%), antiarrhythmic drugs (5.7% vs. 9.6%), anticoagulants (10.9% vs. 15.9%), antiplatelets (49.3% vs. 59.1%), and statins (42.3% vs. 51.2%) were more frequently prescribed to men.

Dependence of QRS duration on sex and height

Multivariable linear regression was used to assess the relation of QRS duration with sex, height, and other baseline covariates. Because men in the study were limited to QRS ≥ 140 ms, 146 women with QRS < 140 ms were excluded from this analysis to have balanced selection criteria. Sex, height, body mass index, LVEF, PR interval, diabetes, chronic lung disease, and the prescription of loop diuretics were identified to be independently associated with QRS duration (Table 3). Among patients with QRS duration ≥ 140 ms, women had a 5.1 ms shorter QRS duration than men. In the

DOI: 10.1002/ehf2.12914
Table 1 Baseline characteristics

| Patient characteristics | All patients (N = 3620) | Females (N = 1569) | Males (N = 2051) | P valueb |
|-------------------------|-------------------------|--------------------|------------------|----------|
| **Baseline characteristics** |                         |                    |                  |          |
| **Baseline characteristics N (%) or mean ± standard deviation** |                         |                    |                  |          |
| **Patient demographics** |                         |                    |                  |          |
| Age (years) | 64.9 ± 11.0 | 65.4 ± 11.0 | 64.5 ± 11.0 | 0.013 |
| Height (cm) | 169.0 ± 10.5 | 161.1 ± 7.4 | 175.1 ± 8.1 | <0.0001 |
| BMI (kg/m²) | 28.9 ± 6.5 | 29.2 ± 7.0 | 28.7 ± 6.1 | 0.019 |
| Underweight (BMI < 18.5) | 61 (1.7%) | 39 (2.5%) | 22 (1.1%) | 0.002 |
| Obese (BMI > 30) | 1348 (37.2%) | 625 (39.8%) | 723 (35.3%) | 0.005 |
| **Physical assessment** |                         |                    |                  |          |
| Heart rate (bpm) | 72.0 ± 12.2 | 73.0 ± 11.9 | 71.1 ± 12.5 | <0.0001 |
| Systolic blood pressure (mmHg) | 125.5 ± 19.7 | 125.5 ± 19.9 | 125.6 ± 19.6 | 0.94 |
| LVEF (%) | 25.5 ± 6.3 | 25.8 ± 6.2 | 25.3 ± 6.3 | 0.008 |
| QRS duration (ms) | 162.6 ± 16.6 | 158.4 ± 16.7 | 165.9 ± 15.8 | <0.0001 |
| QRS duration excluding <140 ms | 163.8 ± 15.9 | 160.8 ± 15.6 | 165.9 ± 15.8 | <0.0001 |
| Indexed QRS duration (ms/m) | 96.4 ± 10.4 | 98.4 ± 10.8 | 94.9 ± 9.7 | <0.0001 |
| PR interval (ms) | 171.8 ± 21.0 | 167.7 ± 21.2 | 174.9 ± 20.3 | <0.0001 |
| Dyspnoea | 1068 (29.5%) | 484 (30.8%) | 584 (28.5%) | 0.12 |
| Rales/crackles | 183 (5.1%) | 69 (4.4%) | 114 (5.6%) | 0.13 |
| Murmurs (systolic or diastolic) | 512 (14.1%) | 246 (15.7%) | 266 (13.0%) | 0.024 |
| S3 gallop | 128 (3.5%) | 54 (3.4%) | 74 (3.6%) | 1.00 |
| Peripheral oedema | 501 (13.8%) | 228 (14.5%) | 273 (13.3%) | 0.31 |
| **Blood chemistry** |                         |                    |                  |          |
| Creatinine (mg/dL) | 1.19 ± 0.84 | 1.09 ± 0.76 | 1.27 ± 0.89 | <0.0001 |
| Creatinine, indexed for weight (mg/dL/100 kg) | 1.55 ± 1.32 | 1.54 ± 1.32 | 1.55 ± 1.32 | 0.78 |
| GFR (mL/min/1.73 m²) | 62.0 ± 20.4 | 59.6 ± 19.7 | 63.8 ± 20.8 | <0.0001 |
| Haemoglobin (g/dL) | 13.3 ± 1.7 | 12.7 ± 1.5 | 13.7 ± 1.7 | <0.0001 |
| Sodium (mmol/L) | 139.0 ± 3.9 | 139.3 ± 3.5 | 138.8 ± 4.2 | <0.0001 |
| Potassium (mmol/L) | 4.33 ± 0.50 | 4.28 ± 0.50 | 4.37 ± 0.50 | <0.0001 |
| **Heart failure history and symptoms** |                         |                    |                  |          |
| Time since heart failure diagnosis (months) | 28.0 ± 45.0 | 26.9 ± 44.6 | 28.9 ± 45.2 | 0.26 |
| Prior hospitalization for heart failure (N, %) | 1744 (48.2%) | 763 (48.6%) | 981 (47.8%) | 0.97 |
| NYHA class |                   |                    |                  |          |
| Class II | 1748 (48.3%) | 696 (44.4%) | 1052 (51.3%) | <0.001 |
| Class III | 1824 (50.4%) | 860 (54.8%) | 964 (47.0%) | 0.97 |
| Class IV | 48 (1.3%) | 13 (0.8%) | 35 (1.7%) | <0.001 |
| **Cardiovascular medical history** |                         |                    |                  |          |
| Dilated/congestive cardiomyopathy | 2380 (65.7%) | 1179 (75.1%) | 1201 (58.6%) | <0.0001 |
| Ischaemic cardiomyopathy | 1143 (31.6%) | 332 (21.2%) | 811 (39.5%) | <0.0001 |
| Myocardial infarction | 684 (18.9%) | 197 (12.6%) | 487 (23.7%) | <0.0001 |
| Hypertension | 2,198 (60.7%) | 945 (60.2%) | 1,253 (61.1%) | 0.66 |
| Pulmonary hypertension | 211 (5.8%) | 108 (6.9%) | 103 (5.0%) | 0.018 |
| Mitral valve disease | 582 (16.1%) | 291 (18.5%) | 291 (14.2%) | <0.001 |
| Previous ICD | 227 (6.3%) | 61 (3.9%) | 166 (8.1%) | <0.0001 |
| Previous pacemaker | 37 (1.0%) | 12 (0.8%) | 25 (1.2%) | 0.24 |
| Atrial fibrillation | 462 (12.8%) | 161 (10.3%) | 301 (14.7%) | <0.0001 |
| AV block | 175 (4.8%) | 55 (3.5%) | 120 (5.9%) | 0.001 |
| Left bundle branch block | 3617 (99.9%) | 1567 (99.9%) | 2050 (100.0%) | 1.00 |
| Stroke | 221 (6.1%) | 93 (5.9%) | 128 (6.2%) | 0.73 |
| Peripheral vascular disease | 195 (5.4%) | 59 (3.8%) | 136 (6.6%) | <0.001 |

(Continues)
model, 2.8 ms of this difference was attributed to sex and 2.0 ms to the difference in height (Figure 3).

**Discussion**

This manuscript describes sex differences in the baseline clinical characteristics and QoL of patients randomized in the AdaptResponse trial, which is the largest randomized CRT study to date, and recruited the highest percentage of female patients (43.3% of those randomized), approaching the actual proportion of women among patients with HF with reduced ejection fraction. The most important findings were that, compared with men, women more often had advanced HF symptoms, were more often depressed, and scored significantly lower on measures of QoL despite having less comorbidities and less frequent ischaemic cardiomyopathy. Differences in medication prescriptions were also noted. QRS duration remained shorter in women even when other baseline variables, including shorter height, were accounted for.

Historically, in clinical CRT trials, women have only represented roughly 20–30% of the study population (Table 4). Consequently, CRT trial results and meta-analyses primarily reflect outcomes in men, rendering it inherently difficult to interpret possible differences between the sexes in response to CRT. Underrepresentation of women in CRT trials may be the result of the fact that men are actually more often referred and historically enrol more frequently in HF trials. In addition, some evidence suggests that men are treated more aggressively for heart disease and are more likely to receive guideline-recommended treatment, which is suggestive of potential referral bias.

AdaptResponse differs from previous CRT studies in the inclusion criteria. The trial has exclusively enrolled patients with LBBB and without AV block. Compared with previous CRT trials (Table 4), AdaptResponse enrolled more women, more patients with NYHA class II (48%), fewer patients with ischaemic heart disease, patients received less angiotensin-converting enzyme inhibitor/angiotensin receptor blocker and loop diuretics, less patients had a history of AF, and more patients had diabetes.

Adding multiple inclusion criteria not previously used in CRT trials has likely contributed to the increased female enrolment in AdaptResponse. The lower QRS duration cut-off for women has broadened our patient cohort, potentially enrolment of female patients in AdaptResponse. The inclusion criterion of intact AV conduction has therefore selected more women than men. We analysed and could not confirm a correlation between female gender of the site’s primary investigator and enrolment of female patients in AdaptResponse.
Irrespective of patient sex, the inclusion criteria may have selected patients who are less sick (normal AV conduction and absence of permanent atrial arrhythmias) and are expected to benefit from CRT (LBBB).

The current analysis identified considerable differences in baseline characteristics between male and female CRT recipients. In line with previous CRT studies, women were less likely to have an ischaemic aetiology of cardiomyopathy (Table 1). Furthermore, also in concordance with other studies, there was a striking difference in the pattern of comorbidities between the sexes. Men were more likely to have AF and renal dysfunction compared with women,7,35 both factors that have been associated with poorer prognosis and higher risk of death in patients with a previous myocardial infarction and low LVEF.36

Interestingly, despite having less comorbid conditions and similar time since HF diagnosis, women had a higher HF symptom burden, as evidenced by the NYHA class distribution and the KCCQ physical limitation and total symptom scores. The adverse impact of the disease on well-being is also greater in women, as seen from the KCCQ QoL score, the EQ-5D health score, and the higher incidence of depression. These findings are in line with a previous report on patients with HF with reduced ejection fraction in pharmacological trials.32

An important finding in the early CRT trials, including Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) trial, Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT), and Resynchronization–Defibrillation for Ambulatory Heart Failure Trial (RAFT), was the observation of substantially better outcome in women than men.7,19,20,35 A potential explanation could be that women more frequently have LBBB and non-ischaemic cardiomyopathy, which are both related to an improved response to CRT,11 due to greater LV reverse remodelling.37 Indeed, a meta-analysis of these three major CRT trials demonstrated a 76% reduction of mortality among female CRT recipients with LBBB and QRS duration of 130–150 ms, without similar benefit reported in men.5 In addition, women have smaller hearts and a shorter QRS duration at baseline compared with men and may therefore have complete LBBB at a shorter QRS duration.13 Several reports have also suggested that women benefit from CRT at shorter QRS durations than men.4,7,38 It has been suggested...
FIGURE 2 The EQ-5D score. (A) The five descriptive questions of the EQ-5D-3L Questionnaire for dimensions mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. These were reported with three answer categories indicating no, some, or extreme problems. The bars indicate the percentage of patients reporting any problems, including the latter two answer categories. The annotated \( P \) values are from Fisher’s exact tests and compare by sex. (B) Summary of self-rated health collected on a visual analog scale (range 0–100). The bars show the mean health score annotated with 95% confidence interval for the mean and a \( P \) value from Student’s \( t \)-test comparing sexes.

Table 2 Baseline medication

| Medication prescribed | All patients (N = 3620) | Females (N = 1569) | Males (N = 2051) | \( P \) value* |
|-----------------------|-------------------------|--------------------|------------------|--------------|
| Beta-blocker          | 3237 (89.4%)            | 1413 (90.1%)       | 1824 (88.9%)     | 0.42 |
| ACE inhibitor, ARB\(^b\) or both | 3036 (83.9%) | 1313 (83.7%) | 1723 (84.0%) | 0.59 |
| ACE inhibitor         | 1865 (51.5%)            | 746 (47.5%)        | 1119 (54.6%)     | \(<0.0001 |
| ARB\(^b\)             | 1218 (33.6%)            | 590 (37.6%)        | 628 (30.6%)      | \(<0.0001 |
| ARNI\(^b\)            | 369 (10.2%)             | 152 (9.7%)         | 217 (10.6%)      | 0.37 |
| MRA                   | 1703 (47.0%)            | 744 (47.4%)        | 959 (46.8%)      | 0.79 |
| Ivabradine            | 133 (3.7%)              | 59 (3.8%)          | 74 (3.6%)        | 0.86 |
| Diuretic\(^c\)        | 2318 (64.0%)            | 1069 (68.1%)       | 1249 (60.9%)     | \(<0.0001 |
| Loop                  | 2161 (59.7%)            | 995 (63.4%)        | 1166 (56.9%)     | \(<0.0001 |
| Thiazide              | 273 (7.5%)              | 125 (8.0%)         | 148 (7.2%)       | 0.45 |
| Potassium sparing     | 10 (0.3%)               | 7 (0.4%)           | 3 (0.1%)         | 0.11 |
| Digitalis glycosides  | 177 (4.9%)              | 80 (5.1%)          | 97 (4.7%)        | 0.64 |
| Antiarrhythmic        | 286 (7.9%)              | 90 (5.7%)          | 196 (9.6%)       | \(<0.0001 |
| Calcium channel blocker | 245 (6.8%)         | 102 (6.5%)         | 143 (7.0%)       | 0.59 |
| Vasodilator           | 426 (11.8%)             | 163 (10.4%)        | 263 (12.8%)      | 0.022 |
| Antiocoagulant        | 497 (13.7%)             | 171 (10.9%)        | 326 (15.9%)      | \(<0.0001 |
| Antiplatelet          | 1987 (54.9%)            | 774 (49.3%)        | 1213 (59.1%)     | \(<0.0001 |
| Statin                | 1713 (47.3%)            | 663 (42.3%)        | 1050 (51.2%)     | \(<0.0001 |

ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor nephrilysin inhibitor; MRA, mineralocorticoid receptor antagonist.

*\( P \) values compare male and female patients. Test used is Student’s \( t \)-test.

\(^b\) Patients who receive an ARNI are also included in the ARB count.

\(^c\) Diuretic total includes all patients with one or more medications that are classified as loop diuretic, thiazide, or potassium sparing diuretic.

that shorter height\(^5\) and longer QRS duration\(^3\) rather than sex, are independent predictors of greater beneficial effect of CRT and that sex may act as a surrogate for height, QRS, LV dimensions, or HF aetiology. Importantly, our analysis of QRS duration (Table 3) shows that in AdaptResponse, even when accounting for height, aetiology, and other
### Table 3 Multivariable linear regression model for QRS duration

| Variable                    | Effect on QRS duration (ms) | 95% confidence interval   | P value  |
|-----------------------------|-----------------------------|---------------------------|----------|
| Intercept                   | 164.5                       | −4.23 to −1.40            | <0.0001  |
| Female                      | −2.81                       | −0.07 to 0.03             | 0.50     |
| Age                         | −0.02 per year              | 0.08 to 0.21              | <0.0001  |
| Height                      | 0.15 per cm                 | 0.25 to 0.57              | <0.0001  |
| BMI                         | 0.41 per kg/m²              | −0.96 to 1.13             | 0.87     |
| NYHA class III/IV           | −0.35 per percent           | −0.43 to −0.26            | <0.0001  |
| PR interval                 | 0.08 per ms                 | 0.05 to 0.11              | <0.0001  |
| Ischaemic aetiology         | −0.76                       | −1.93 to 0.41             | 0.20     |
| Atrial fibrillation         | 0.58                        | −0.99 to 2.14             | 0.47     |
| Diabetes                    | −2.21                       | −3.34 to −1.09            | 0.0001   |
| Chronic lung disease        | −2.33                       | −3.78 to −0.88            | 0.002    |
| Renal dysfunction           | −0.58                       | −1.99 to 0.84             | 0.42     |
| Loop diuretics              | 1.76                        | 0.68 to 2.83              | 0.001    |

**BMI, body mass index; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.**

A total of 146 female patients with QRS < 140 ms were excluded.

*Variables removed from model: prior heart failure hospitalization, dilated cardiomyopathy, coronary artery disease, myocardial infarction, hypertension, mitral valve disease, stroke, peripheral vascular disease, anaemia, hypothyroidism, sleep apnoea, cancer, depression, beta-blocker, angiotensin-converting enzyme inhibitor, angiotensin receptor blocker.*

*Intercept represents a male patient, 65 years, height 175 cm, BMI 29 kg/m², LVEF 30%, PR interval 180 ms, NYHA class II, no comorbidities, no diuretics.*

*QRS duration increases for BMI between 18.5 and 30.*

---

**FIGURE 3** Relation of QRS duration with height and gender. Solid curves represent the smoothed average QRS duration for height and gender (penalized B-splines). Vertical dashed lines represent average height for women and men.

---

Baseline characteristics, women remained to have shorter QRS duration. The current investigation of differences in patient characteristics will be used in outcome analyses that will account for confounding factors and address the question whether sex is linked to response and, if so, whether this is attributed to sex alone or to sex-associated patient characteristics.
| Parameter                  | MIRACLE\(^1\(^5\)\) | COMPANION\(^1\(^6\)\) | CARE-HF\(^1\(^7\),\(^2\(^7\)\) | REVERSE\(^1\(^8\)\) | MADIT-CRT\(^1\(^9\)\) | RAFT\(^2\(^0\)\) | NCDR\(^4\) | ESC CRT Survey I\(^2\(^9\)\) | AdaptResponse |
|---------------------------|----------------------|------------------------|-----------------------------|-------------------|---------------------|----------|--------|---------------------|---------------|
| Patients without CRT (n)  | 225                  | 308                    | 404                         | 0                 | 0                   | 0        | 0      | 0                   | 0             |
| Patients CRT-P (n)        | 228                  | 617                    | 409                         | 99                | 0                   | 0        | 0      | 3256                | 161           |
| Patients CRT-D (n)        | 0                    | 595                    | 0                            | 509               | 1089                | 0        | 0      | 0                   | 3449          |
| FU duration (months)      | 6                    | 16                     | 29                           | 12                | 28                  | 40       | 0      | NR                  | Ongoing       |
| Age (years)               | 65                   | 67                     | 65                           | 65                | 66                  | 69       | 70     | 65                  | 65            |
| Women (%)                 | 32                   | 33                     | 27                           | 21.5              | 26                  | 17       | 41     | 24                  | 43            |
| Ischaemic heart disease (%) | 54                 | 55                     | 38                           | 55                | 14                  | 69       | 51     | 45                  | 31            |
| NYHA I/II (%)             | 0                    | 0                      | 0                            | 100               | 100                 | 79       | 14     | 41                  | 48            |
| MUVHF                     | 59                   | NR                     | 45                           | 28                | NR                  | 42       | NR     | NR                  | NR            |
| Six-minute hall walk (m)  | 298                  | 262                    | NR                           | 395               | 359                 | 351      | NR     | NR                  | NR            |
| LVEF (%)                  | 22                   | 21                     | 26                           | 27                | 24                  | 23       | 24     | 29                  | 26            |
| QRS (ms)                  | 166                  | 160                    | 165                          | 153               | NR                  | 157      | 156    | 160                 | 163           |
| Heart rate (bpm)          | 74                   | 72                     | 70                           | 67                | NR                  | NR       | NR     | 70                  | 72            |
| Systolic BP mmHg          | 114                  | 111                    | 117                          | 125               | 124                 | NR       | NR     | 122                 | 126           |
| ACEi/ARB (%)              | 92                   | 89                     | 95                           | 97                | 98                  | 96       | 85     | 86\(^a\)            | 83            |
| Beta-blockers (%)         | 59                   | 68                     | 72                           | 95                | 93                  | 90       | 89\(^a\) | 89\(^a\)             | 89            |
| Diuretics (%)             | 94                   | 95                     | 99                           | 80                | 75                  | 85       | NR     | 81\(^a\)            | 64            |
| AF (%)                    | NR                   | NR                     | 21                           | 17                | 11                  | 13       | NR     | 41                  | 13            |
| Diabetes (%)              | NR                   | 41                     | 21                           | 23                | 30                  | 33       | 37     | 31                  | 35            |
| LBBD (%)                  | NR                   | 71                     | NR                           | 77                | 70                  | 73       | 100    | 73                  | 99\(^a\) |

ACEi, angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; BP, blood pressure; CARE-HF, The Cardiac Resynchronization - Heart Failure trial; COMPANION, The Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure trial; CRT, cardiac resynchronization therapy; ESC, European Society of Cardiology; FU, follow-up; LBBD, left bundle branch block; LVEF, left ventricular ejection fraction; MADIT-CRT, Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy; MIRACLE, Multicenter InSync Randomized Clinical Evaluation trial; MLWHF, Minnesota Living with Heart Failure Questionnaire; NCDR, National Cardiovascular Data Registry; NR, not reported; NYHA, New York Heart Association; RAFT, Resynchronization–Defibrillation for Ambulatory Heart Failure Trial; REVERSE, Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction.

\(^a\)At discharge.

\(^b\)Investigator reported.
Conclusions

In the largest CRT trial to date, women showed a higher HF symptom burden and differed from men in a large number of clinical characteristics, including characteristics known to be associated with response to CRT. In particular, accounting for other clinical factors, QRS duration was shorter in women.

Conflict of interest

B.L.W. participated in Physician Advisory Committees of Medtronic, Abbott, Philips and reports honoraria from Medtronic, Abbott, Philips. D.B. is a mid-career investigator supported by the Heart and Stroke Foundation of Ontario and by the University of Ottawa Chair in Electrophysiology Research. He has received major research funding from Medtronic, Boston Scientific, Boehringer Ingelheim, Bayer, Biotronik, Pfizer, and Bristol Myers Squibb. M.R.G. is a consultant to Medtronic and Boston Scientific and receives honoraria from Medtronic, Boston Scientific, and EBR. A.S.H., K., and W.M. have no conflicts of interest to disclose. S.J. and B.G. are employed by Medtronic. C.L. participated in a Medtronic advisory board and reports honoraria received from Medtronic, Biotronik, LivaNova, Boston Scientific, and Abbott. G.F. participated in committees of trials sponsored by Bayer, Novartis, Servier, Vifor, BI, and Medtronic.

Funding

The AdaptResponse study is funded in its entirety by Medtronic plc.

Supporting information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Data S1. Supporting information

References

1. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Niňooyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Rutlege LM, Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2016; 37: 2129–2200.

2. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi Jr, Johnson MR, KasperEK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, MitchellJE, PetersonPN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62: e147–e239.

3. Vernooy K, van Deursen CJ, Strik M, Prinzen FW. Strategies to improve cardiac resynchronization therapy. Nat Rev Cardiol 2014; 11: 481–493.

4. Zusterzeel R, Curtis JP, Canos DA, Sanders WE, Selzman KA, Pina IL, Spatz ES, Bao H, Ponirakas A, Varosy PD, Masoudi FA, Strauss DG. Sex-specific mortality risk by QRS morphology and duration in patients receiving CRT: results from the NCDR. J Am Coll Cardiol 2014; 64: 887–894.

5. Zusterzeel R, Selzman KA, Sanders WE, Canos DA, O’Callaghan KM, Carpenter JL, Pina IL, Strauss DG. Cardiac resynchronization therapy in women: US Food and Drug Administration meta-analysis of patient-level data. JAMA Intern Med 2014; 174: 1340–1348.

6. Ignaszewski MT, Daugherty SL, Russo AM. Implantable cardioverter-defibrillators and cardiac resynchronization therapy in women. Heart Fail Clin 2019; 15: 109–125.

7. Arshad A, Moss AJ, Foster E, Padeletti L, Barsheshet A, Goldenberg I, Greenberg H, Hall WJ, McNitt S, Zareba W, Solomon S, Steinberg JS, Committee M-CE. Cardiac resynchronization therapy is more effective in women than in men: the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy) trial. J Am Coll Cardiol 2011; 57: 813–820.

8. Leyva F, Foley PW, Chailil S, Irwin N, Smith RE. Female gender is associated with a better outcome after cardiac resynchronization therapy. Circulation 2010; 122: 2022–2030.

9. Goldenberg I, Moss AJ, Hall WJ, Foster E, Goldberger JJ, Santucci P, Shin T, Solomon S, Steinberg JS, Wilber D, Barsheshet A, McNitt S, Zareba W, Klein H. Predictors of response to cardiac resynchronization therapy in the Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT). Circulation 2011; 124: 1527–1536.

10. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, Loh E, Kocovic M, Tchou P. Female gender is associated with a better outcome after cardiac resynchronization therapy. Circulation 2010; 122: 2022–2030.

11. Vernooy K, van Deursen CJ, Strik M, Prinzen FW. Strategies to improve cardiac resynchronization therapy. Nat Rev Cardiol 2014; 11: 481–493.

12. Zusterzeel R, Curtis JP, Canos DA, Sanders WE, Selzman KA, Pina IL, Spatz ES, Bao H, Ponirakas A, Varosy PD, Masoudi FA, Strauss DG. Sex-specific mortality risk by QRS morphology and duration in patients receiving CRT: results from the NCDR. J Am Coll Cardiol 2014; 64: 887–894.

13. Strauss DG, Selvester RH, Wagner GS. Defining left bundle branch block in the era of cardiac resynchronization therapy: meta-analysis of randomized controlled trials. Am J Cardiol 2012; 163: 260–267 e263.

14. Vernooy K, van Deursen CJ, Strik M, Prinzen FW. Strategies to improve cardiac resynchronization therapy. Nat Rev Cardiol 2014; 11: 481–493.

15. Vernooy K, van Deursen CJ, Strik M, Prinzen FW. Strategies to improve cardiac resynchronization therapy. Nat Rev Cardiol 2014; 11: 481–493.
Ellestad M, Trupp RJ, Underwood J, Pickering F, Truex C, McAttee P, Messenger J. Cardiac resynchronization in chronic heart failure. *N Engl J Med* 2002; 346: 1845–1853.

Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW, Feldman AM. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. *N Engl J Med* 2004; 350: 2140–2150.

Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Klein W, Tavazzi L. Baseline characteristics of patients recruited into the CARE-HF study. *Eur J Heart Fail* 2005; 7: 205–214.

Linde C, Gold M, Abraham WT, Daubert JC. Baseline characteristics of patients randomized in the Resynchronization Versus Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) study. *Congest Heart Fail* 2008; 14: 66–74.

Moss AJ, Hall WJ, Cannon DS, Klein H, Brown MW, Daubert JP, Estes NA 3rd, Foster E, Greenberg H, Higgins SL, Pfeffer MA, Solomon SD, Wilber D, Zareba W. Cardiac-resynchronization therapy for the prevention of heart-failure events. *N Engl J Med* 2009; 361: 1292–1303.

Ang PCI, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, Hohnloser SH, Nichol G, Birnie DH, Sapp JL, Yee R, Healey JS, Rouleau JL. Cardiac-resynchronization therapy for mild-to-moderate heart failure. *N Engl J Med* 2010; 363: 2385–2395.

Krum H, Lembke B, Birnie D, Lee KL, Aounuma K, Starling RC, Gasparini M, Gorcsan J, Rogers T, Sambelashvili A, Kalmes A, Martin D. A novel algorithm for individualized cardiac resynchronization therapy: rationale and design of the adaptive cardiac resynchronization therapy trial. *Am Heart J* 2012; 163: 747–752 e741.

Martin DO, Lembke B, Birnie D, Krum H, Lee KL, Aounuma K, Gasparini M, Starling RC, Milasinovic G, Rogers T, Sambelashvili A, Gorcsan J, Houmuse M. Investigation of a novel algorithm for synchronized left-ventricular pacing and ambulatory optimization of cardiac resynchronization therapy: results of the adaptive CRT trial. *Heart Rhythm* 2012; 9: 1807–1814.

Birnie D, Lembke B, Aounuma K, Krum H, Lee KL, Gasparini M, Starling RC, Milasinovic G, Gorcsan J, Houmuse M, Abeayratne A, Sambelashvili A, Martin DO. Clinical outcomes with synchronized left ventricular pacing: analysis of the adaptive CRT trial. *Heart Rhythm* 2013; 10: 1368–1374.

Singh JP, Abraham WT, Chung ES, Rogers T, Sambelashvili A, Coles JA Jr, Martin DO. Clinical response with adaptive CRT algorithm compared with CRT with echocardiography-optimized atrioventricular delay: a retrospective analysis of multicentre trials. *Europan* 2013; 15: 1622–1628.

Filippatos G, Birnie D, Gold MR, Gerritse B, Harsi A, Jacobs S, Kusano K, Leclercq C, Mullens W, Wilkoff BL. Rationale and design of the AdaptResponse trial: a prospective randomized study of cardiac resynchronization therapy with preferential adaptive left ventricular-only pacing. *Eur J Heart Fail* 2017; 19: 950–957.

Bozkurt B, Khalaf S. Heart failure in women. *Methodist Debakey Cardiovasc J* 2017; 13: 216–223.

Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L. The effect of cardiac resynchronization on morbidity and mortality in heart failure. *N Engl J Med* 2005; 352: 1539–1549.

Dickstein K, Normand C, Auricchio A, Bogale N, Cleland JG, Gitt AK, Stellbrink C, Anker SD, Filippatos G, Gasparini M, Hindricks G, Blomstrom Lundqvist C, Ponikowski P, Ruschitzka F, Botto GL, Bulava A, Duray G, Israel C, Leclercq C, Margitfalvi P, Cano O, Plummer C, Sarigul NU, Sterlinski M, Linde C. CRT Survey II: a European Society of Cardiology survey of cardiac resynchronisation therapy in 11 088 patients—who is doing what to whom and how? *Eur J Heart Fail* 2018; 20: 1039–1051.

Tahhan AS, Vaduganathan M, Greene SJ, Fonarow GC, Fiuzat M, Jessup M, Lindenfeld J, O’Connor CM, Butler J. Enrollment of older patients, women, and racial and ethnic minorities in contemporary heart failure clinical trials: a systematic review. *JAMA Cardiol* 2018; 3: 1011–1019.

Lenzen MJ, Bosra F, Scholte op Reimer WJ, Falla F, Boersma E, Siemons ML, Cleland JG, Komajda M. Management of patients with heart failure in clinical practice: differences between men and women. *Heart* 2008; 94: e10.

Burstein JM, Yan R, Weller I, Abramson BL. Management of congestive heart failure: a gender gap may still exist. *Observations from a contemporary cohort. BMC Cardiovasc Disord* 2003; 3: 1.

Dewan P, Rorth R, Jhund PS, Shen L, Raparelli V, Petrie MC, Abraham WT, Desai AS, Dickstein K, Kober L, Mogensen UM, Packer M, Rouleau JL, Solomon SD, Swedberg K, Zile MR, McMurray J. Differential impact of heart failure with reduced ejection fraction on men and women. *J Am Coll Cardiol* 2019; 73: 29–40.

Kloosterman M, Maass AH. Sex differences in optimal atrioventricular delay in patients receiving cardiac resynchronization therapy. *Clin Res Cardiol* 2019.

Biton Y, Zareba W, Goldenberg I, Klein H, McNitt S, Polonsky B, Moss AJ, Kutyifa V. Sex differences in long-term outcomes with cardiac resynchronization therapy in mild heart failure patients with left bundle branch block. *J Am Heart Assoc* 2015; 4.

Linde C, Abraham WT, Gold MR, St John Sutton M, Ghio S, Daubert JC. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. *J Am Coll Cardiol* 2008; 52: 1834–1843.

Goldenberg I, Vyas AK, Hall WJ, Moss AJ, Wang H, He H, Zareba W, McNitt S, Andrews ML. Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. *J Am Coll Cardiol* 2008; 51: 288–296.

Gold MR, Thebault C, Linde C, Abraham WT, Gerritse B, Ghio S, St John Sutton M, Daubert JC. Effect of QRS duration and morphology on cardiac resynchronization therapy outcomes in mild heart failure: results from the Resynchronization Versus Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) study. *Circulation* 2012; 126: 822–829.

Zusterzeel RP, Spatz ES, Curtis JP, Sanders WE, Selzman KA, Pina IL, Bao H, Ponirakis A, Varosy PD, Massoudi FA, Canos DA, Strauss DG. Cardiac resynchronization therapy in women versus men: observational comparative effectiveness study from the National Cardiovascular Data Registry. *Circ Cardiovasc Qual Outcomes* 2015; 8: S4–S11.

Cleland JG, Abraham WT, Linde C, Gold MR, Young JB, Claude Daubert J, Sherfesee I, Wells GA, Tang AS. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. *Eur Heart J* 2013; 34: 3547–3556.